XM
OVID icon

XTX Markets’s Ovid Therapeutics OVID Stock Holding History

XTX Markets’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$78K Buy
33,836
+18,065
+115% +$84.2K 0.16% 173
2020
Q3 		$91K Buy
+15,771
New +$106K 0.44% 78

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

XTX Markets's OVID Position: Q4 2020 in Review

XTX Markets increased its Ovid Therapeutics (OVID) stake by 115% in Q4 2020, buying an estimated $84.2K and bringing the position to 33,836 shares worth $78K. The position accounts for 0.16% of the portfolio, ranked #173.

XTX Markets first reported a position in OVID in Q3 2020 and has held it in 2 quarters since. The position peaked at $91K in Q3 2020. 83 funds tracked by Wall St. Rank hold OVID as of Q4 2020.

  • XTX Markets held 33,836 shares of Ovid Therapeutics worth $78K as of Q4 2020.
  • XTX Markets bought 18,065 Ovid Therapeutics shares in Q4 2020, an estimated $84.2K.
  • Ovid Therapeutics made up 0.16% of XTX Markets's portfolio in Q4 2020, its #173 holding.
  • XTX Markets first reported a position in Ovid Therapeutics in Q3 2020 and has held it in 2 quarters since.
  • XTX Markets's Ovid Therapeutics position peaked at $91K in Q3 2020.
  • 83 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2020.

Based on XTX Markets's 13F filing for Q4 2020, filed 25 Jan 2021.